Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
RESEARCH TOOLSreports
RNAC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.67 - $41.87
Previous CloseN/A
Volume45.37K
Average Volume (3M)66.63K
Market Cap
$504.47M
Enterprise Value$141.57M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Mar 06, 2025EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-52.64
Shares Outstanding25,725,306
10 Day Avg. Volume48,954
30 Day Avg. Volume66,634
Standard Deviation0.23
R-Squared0.02
Alpha-0.00868
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.43
Price to Cash Flow (P/CF)9.10
P/FCF Ratio16.60
Enterprise Value/Market Cap0.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.79
Enterprise Value/Ebitda-0.54
Forecast
1Y Price Target
$37.50Price Target Upside94.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Cartesian Therapeutics News
PremiumCompany Announcements
Cartesian Therapeutics Sets 2025 Strategy for Descartes-08
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPositive results from the Phase 2b trial of Descartes-08 in participants with myasthenia gravis showed unparalleled efficacy and durability, suggesting strong potential for success in Phase 3.
Innovative TreatmentDescartes-08, the first cell therapy advancing into a Phase 3 trial for an autoimmune disease, represents a groundbreaking approach in the field.
Regulatory ApprovalThe company has received a written agreement from the FDA under the Special Protocol Assessment (SPA) process, indicating strong regulatory alignment for the Phase 3 AURORA trial of Descartes-08 in myasthenia gravis.
Bears Say
Clinical Trial RisksRisks include potential delays in moving candidates through trials and failure to generate favorable clinical data, particularly with Descartes-08 in myasthenia gravis.
Development ChallengesThe company faces challenges in maintaining momentum with its differentiated mRNA CAR-T approach amidst an emerging competitive landscape in cell therapies for autoimmune diseases.
Timeline ConcernsEnrollment is on track to begin with topline results expected prior to mid-27, which could impact investor expectations for near-term milestones.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RNAC FAQ
What was Cartesian Therapeutics’s price range in the past 12 months?
Cartesian Therapeutics lowest stock price was $11.66 and its highest was $41.87 in the past 12 months.
What is Cartesian Therapeutics’s market cap?
Cartesian Therapeutics’s market cap is $504.47M.
When is Cartesian Therapeutics’s upcoming earnings report date?
Cartesian Therapeutics’s upcoming earnings report date is Mar 06, 2025 which is in 11 days.
How were Cartesian Therapeutics’s earnings last quarter?
Cartesian Therapeutics released its earnings results on Nov 07, 2024. The company reported -$1.13 earnings per share for the quarter, missing the consensus estimate of -$0.802 by -$0.328.
Is Cartesian Therapeutics overvalued?
According to Wall Street analysts Cartesian Therapeutics’s price is currently Undervalued.
Does Cartesian Therapeutics pay dividends?
Cartesian Therapeutics does not currently pay dividends.
What is Cartesian Therapeutics’s EPS estimate?
Cartesian Therapeutics’s EPS estimate is -0.83.
How many shares outstanding does Cartesian Therapeutics have?
Cartesian Therapeutics has 25,725,306 shares outstanding.
What happened to Cartesian Therapeutics’s price movement after its last earnings report?
Cartesian Therapeutics reported an EPS of -$1.13 in its last earnings report, missing expectations of -$0.802. Following the earnings report the stock price went down -0.384%.
Which hedge fund is a major shareholder of Cartesian Therapeutics?
Currently, no hedge funds are holding shares in RNAC
---
Cartesian Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.50 (94.91% Upside)
$37.50 (94.91% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 100.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $375.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.89%
12-Months-Change
Fundamentals
Return on Equity
-938.38%
Trailing 12-Months
Asset Growth
329.41%
Trailing 12-Months
Company Description
Cartesian Therapeutics
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.
---
RNAC Stock 12 Month Forecast
Average Price Target
$37.50
▲(94.91% Upside)
Technical Analysis
Fate Therapeutics
―
Adaptimmune Therapeutics
―
ImmunityBio
―
Crispr Therapeutics AG
―
Cabaletta Bio
―
Best Analysts Covering RNAC
1 Year
1 Year Success Rate
11/30 ratings generated profit
1 Year Average Return
-15.18%
reiterated a buy rating 7 months ago
Copying John Newman's trades and holding each position for 1 Year would result in 36.67% of your transactions generating a profit, with an average return of -15.18% per trade.
---